ABBV-399, a C-Met Antibody–Drug Conjugate That Targets Both MET –Amplified and C-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1568
Full Text
Open PDFAbstract
Available in full text
Date
August 29, 2016
Authors
Publisher
American Association for Cancer Research (AACR)